0 CHECKOUT

Anesthetic Effect - Pipeline Review, H1 2015

  • ID: 3266302
  • April 2015
  • Region: Global
  • 92 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Advicenne Pharma
  • Laboratoires Thea S.A.
  • Merck & Co., Inc.
  • Paion AG
  • Phosphagenics Limited
  • Physica Pharma
  • MORE

‘Anesthetic Effect - Pipeline Review, H1 2015’, provides an overview of the Anesthetic Effect’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anesthetic Effect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anesthetic Effect and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Advicenne Pharma
  • Laboratoires Thea S.A.
  • Merck & Co., Inc.
  • Paion AG
  • Phosphagenics Limited
  • Physica Pharma
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Anesthetic Effect Overview
Therapeutics Development
Pipeline Products for Anesthetic Effect - Overview
Pipeline Products for Anesthetic Effect - Comparative Analysis
Anesthetic Effect - Therapeutics under Development by Companies
Anesthetic Effect - Therapeutics under Investigation by Universities/Institutes
Anesthetic Effect - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Anesthetic Effect - Products under Development by Companies
Anesthetic Effect - Products under Investigation by Universities/Institutes
Anesthetic Effect - Companies Involved in Therapeutics Development
Advicenne Pharma
Biolab Sanus Farmaceutica Ltda.
Drawbridge Pharmaceuticals Pty Ltd
Jiangsu Hengrui Medicine Co., Ltd.
Juniper Pharmaceuticals, Inc.
Laboratoires Thea S.A.
Lipicard Technologies Limited
Merck & Co., Inc.
NanoMedex Pharmaceuticals, Inc.
Paion AG
Phosphagenics Limited
Physica Pharma
Proteus SA
Sphaera Pharma Pvt. Ltd.
Taiwan Liposome Company, Ltd.
The Medicines Company
Anesthetic Effect - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(lidocaine + phenylephrine hydrochloride + tropicamide) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(tetracaine + oxymetazoline hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABP-700 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADV-6209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alphaxalone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bupivacaine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carboetomidate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gabafol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lidocaine ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LT-1121 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LT-1123 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
methoxycarbonyl carboetomidate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
methoxycarbonyl etomidate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
neosaxitoxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PB-5109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHY-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
propofol microemulsion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
propofol-DM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
remimazolam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
remimazolam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit NMDA Receptor for Anaesthesia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sugammadex sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anesthetic Effect - Recent Pipeline Updates
Anesthetic Effect - Dormant Projects
Anesthetic Effect - Discontinued Products
Anesthetic Effect - Product Development Milestones
Featured News & Press Releases
Apr 28, 2015: FDA Declines To Approve Merck’s Bridion
Mar 13, 2015: Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection
Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States
Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion
Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan
Oct 10, 2014: Paion Expects Ono’S Remimazolm Decision On Filing In Japan In November 2014
Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
Sep 15, 2014: Drawbridge Pharmaceuticals to present clinical findings of Phaxan at Anesthesiology 2014
Jul 21, 2014: Drawbridge Pharmaceuticals extends Phaxan patent portfolio with divisional patents granted for other neuroactive steroids
Jun 18, 2014: Drawbridge Pharmaceuticals granted new anaesthesia patent for Phaxan in China
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Anesthetic Effect, H1 2015
Number of Products under Development for Anesthetic Effect - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Anesthetic Effect - Pipeline by Advicenne Pharma, H1 2015
Anesthetic Effect - Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015
Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2015
Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015
Anesthetic Effect - Pipeline by Juniper Pharmaceuticals, Inc., H1 2015
Anesthetic Effect - Pipeline by Laboratoires Thea S.A., H1 2015
Anesthetic Effect - Pipeline by Lipicard Technologies Limited, H1 2015
Anesthetic Effect - Pipeline by Merck & Co., Inc., H1 2015
Anesthetic Effect - Pipeline by NanoMedex Pharmaceuticals, Inc., H1 2015
Anesthetic Effect - Pipeline by Paion AG, H1 2015
Anesthetic Effect - Pipeline by Phosphagenics Limited, H1 2015
Anesthetic Effect - Pipeline by Physica Pharma, H1 2015
Anesthetic Effect - Pipeline by Proteus SA, H1 2015
Anesthetic Effect - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2015
Anesthetic Effect - Pipeline by Taiwan Liposome Company, Ltd., H1 2015
Anesthetic Effect - Pipeline by The Medicines Company, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Anesthetic Effect Therapeutics - Recent Pipeline Updates, H1 2015
Anesthetic Effect - Dormant Projects, H1 2015
Anesthetic Effect - Dormant Projects (Contd..1), H1 2015
Anesthetic Effect - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Anesthetic Effect, H1 2015
Number of Products under Development for Anesthetic Effect - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Advicenne Pharma
Biolab Sanus Farmaceutica Ltda.
Drawbridge Pharmaceuticals Pty Ltd
Jiangsu Hengrui Medicine Co., Ltd.
Juniper Pharmaceuticals, Inc.
Laboratoires Thea S.A.
Lipicard Technologies Limited
Merck & Co., Inc.
NanoMedex Pharmaceuticals, Inc.
Paion AG
Phosphagenics Limited
Physica Pharma
Proteus SA
Sphaera Pharma Pvt. Ltd.
Taiwan Liposome Company, Ltd.
The Medicines Company

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Baxter International Inc.
  • Purdue Pharma L.P.
  • Hikma Pharmaceuticals PLC
  • Eisai Co
  • Astrazeneca PLC
  • Mylan N.V.